SUBSCRIBE
SUBSCRIBE

TG Therapeutics, Inc.

NEWS
Amneal and Impax to Marry, Creating the 5th Larges
Genetown
3 High-Risk Biotechs That Could Pop or Drop in 2018
February 5, 2018
 · 
3 min read
 · 
Mark Terry
FDA Advisory Committee Scheduled to Review Lipocin
Drug Development
TG Therapeutics Announces Updated Results From the Ongoing Phase II Study of Ublituximab in Patients With MS
February 2, 2018
 · 
6 min read
Business
TG Therapeutics and Jiangsu Hengrui Medicine Announce Global License Agreement for Development and Commercialization of Novel BTK Inhibitor Program for the Treatment of Hematologic Malignancies
January 8, 2018
 · 
7 min read
Drug Development
TG Therapeutics, Inc. Announces Preclinical & Clinical Data Presentations at the 59th American Society of Hematology Annual Meeting
December 11, 2017
 · 
9 min read
Drug Development
TG Therapeutics Announces Initiation of National Cancer Institute/SWOG-Sponsored Randomized Phase II Trial in Follicular Lymphoma
November 27, 2017
 · 
5 min read
Business
TG Therapeutics Provides Business Update and Reports Third Quarter 2017 Financial Results
November 8, 2017
 · 
9 min read
Business
TG Therapeutics to Host Conference Call on Third Quarter 2017 Financial Results and Business Update
November 6, 2017
 · 
1 min read
Drug Development
TG Therapeutics Announces Additional Updated Results from the Ongoing Phase II Study of TG-1101 (ublituximab) in Patients With MS
October 27, 2017
 · 
6 min read
Drug Development
TG Therapeutics Announces Updated Results from the Ongoing Phase II Study of TG-1101 (ublituximab) in Patients with Multiple Sclerosis at the 7th Joint ECTRIMS – ACTRIMS Meeting
October 26, 2017
 · 
6 min read
Drug Development
TG Therapeutics Recaps Clinical Data Presentations at the Upcoming 7th Joint ECTRIMS - ACTRIMS Meeting
October 16, 2017
 · 
6 min read
Philips Wins FDA Nod for Small Parts Ultrasound Tr
Drug Development
TG Therapeutics Provides Update on FDA Meeting for GENUINE Phase III Trial
October 16, 2017
 · 
5 min read
Drug Development
TG Therapeutics Announces Completion of Full Enrollment in the UNITY-CLL Phase III Trial
October 16, 2017
 · 
6 min read
Drug Development
TG Therapeutics Announces Advancement Of Its Anti-PD-L1 Monoclonal Antibody Into Clinical Development
October 5, 2017
 · 
4 min read
Pharm Country
TG Therapeutics Announces TGR-1202 (Umbralisib) Selected For Grant From The National Multiple Sclerosis Society To Support The Development Of TGR-1202 As An Oral B-Cell Targeted Treatment Option In Progressive Multiple Sclerosis (PMS)
September 29, 2017
 · 
6 min read
Drug Development
TG Therapeutics Announces The Phase III ULTIMATE Trials Evaluating TG-1101 In Patients With Multiple Sclerosis Are Now Open For Enrollment
September 15, 2017
 · 
5 min read
Drug Development
TG Therapeutics Announces Successful Outcome From The First Pre-Planned Interim Analysis By Independent DSMB Of The DLBCL Cohort In The UNITY-NHL Phase IIb Trial
August 10, 2017
 · 
4 min read
Load More
AWARDS
  • 2026 - Best Places to Work - Badge (1).png
JOBS